Biotech Values

[DewDiligence]

ENTA—A disagreement on whether the company will remain independent or be sold (suggested by ‘caravon’) makes sense to me at this pivotal time for ENTA.

If a buyout offer is in fact the source of the BoD shake-up (in spite of the modest negative inference discussed in #msg-95841651), then the offer price must be at least $50/sh (and is probably at least $60/sh) else there would be nothing of consequence for the directors to argue about, IMO.